Tiotropium Respimat® improved lung function in children with asthma aged 6-17 and is ...

• New CanoTinA-asthma^® trial results showed adding tiotropium Respimat^® improved lung function in children aged 6-11^1,2
• Additional pooled data support the efficacy and safety of tiotropium Respimat^® in children aged 6-17^3,4
• Safety profile of tiotropium Respimat^® in children aged 1-5 years is consistent with that in older children and adults⁵

(BUSINESS WIRE)-- Boehringer Ingelheim announced today new study results from the Phase III CanoTinA-asthma^® trial that showed adding tiotropium Respimat^® to maintenance asthma therapy significantly improved lung function, as measured by FEV_1(0-3h), in children aged 6-11, compared to placebo (p<0.0001). ...

Source : http://me-newswire.net//news/18592/en...